Awards Tracker Dashboard
Awarded Studies: Target vs Actual · Updated Jul 4, 2026
📌 Notes
- ▸Actual Awards and FCV figures are shown net of cancellations — they reflect studies that remain active after any cancelled or on-hold awards are removed.
- ▸FCV is a derived figure based on two inputs — number of randomization goals and the per-patient budget (PPB). If either input changes for a study, its FCV will change accordingly.
- ▸Dashboard reflects activity within ATOM through Jul 4, 2026.
📊 At a Glance
45%
Studies Awarded (2026 Annual)
141
of 315 target
44%
FCV Captured (2026 Annual)
$44.4M
of $101.4M plan
130%
Vaccine Achieved
39/30
130.0% of Vaccine target
36%
Non-Vaccine Achieved
102/285
35.8% of Non-Vaccine target
103%
Actual FCV/Trial (2026 Annual)
$315K
vs $306K target
⚡ Executive Highlights
Vaccine Both Count and FCV Ahead of Plan
Vaccine count at 130.0% (39/30) and FCV at 113.6% ($19.7M vs $17.3M gross target) — both metrics now ahead of plan. Average vaccine study contract value of $504K is tracking close to, but still below, the implied $590K/study target.
Non-Vaccine FCV at 29.4% — Most Critical Risk
102 NV studies awarded, total FCV generated is only $24.7M against a gross plan of $84.1M (29.4%). Average contract sizes are tracking at $242K vs an implied target of $288K.
Industry Norm: Book-to-Bill of 1.2×
The industry baseline remains 1.2×. For every $1 of recognized revenue, $1.20 in net additions should be secured to defend a ~15% organic growth scale.
Risk-Adjusted Run Rate Gap
The $101.4M gross plan was built with only a 10% cancellation reserve. Actual cancellations are running at 30% — 3.0x the planned rate. To still net the underlying plan at this elevated cancellation rate, front-end pipeline generation must structurally run at $145.1M+ gross. The margin for error in H2 has disappeared.
Pipeline Conversion Imperative
To close the remaining $57.1M FCV deficit, Q3+Q4 win rates must improve significantly. Our current portfolio mix is skewing toward higher-volume, lower-value site startups which dilutes overall profitability.
Quarter Scorecard — 2026
Studies: Actual vs Target by period
| Quarter | TGT | ACT | Rate | FCV TGT | FCV ACT | FCV Rate |
|---|---|---|---|---|---|---|
| Q1-26 | 40 | 40 | 100% | $9.9M | $9.4M | 95% |
| Q2-26 | 55 | 101 | 184% | $19.0M | $35.0M | 184% |
| Q3-26 | 110 | 0 | 0% | $35.6M | $0.0M | 0% |
| Q4-26 | 110 | 0 | 0% | $36.9M | $0.0M | 0% |
Studies Awarded (2026 Annual Results)
Actual vs Target Count (2026 Annual)
ActualTarget
FCV Trend (2026 Annual Results)
Captured vs Plan (2026 Annual)
Actual FCVTarget FCV
Portfolio Mix: Count (for the period)
Actual awards by type (2026 Annual)
Vaccine (39)Non-Vaccine (102)
Portfolio Mix: FCV (for the period)
Actual value by type (2026 Annual)
Vaccine ($19.7M)Non-Vaccine ($24.7M)
Portfolio Mix: T.A (Therapeutic Area, by FCV)
0 studies · $0.0M total FCV
No Data
🧬 ACTUAL FCV BY STRATIFICATION — FCV VALUE BANDS (2026 Annual)
Awarded FCV by FCV Value Band
Actuals from Awarded List · grouped by contract value
Stratification Detail
Goal band share of total goals, FCV and study count
| FCV BAND | STUDIES | % GOALS | FCV | % FCV | AVG FCV/STUDY |
|---|---|---|---|---|---|
| < $100K | 36 | 26% | $2.3M | 5% | $64K |
| $100K–$500K | 83 | 59% | $20.6M | 46% | $248K |
| $500K–$1M | 12 | 9% | $8.8M | 20% | $733K |
| $1M–$5M | 10 | 7% | $12.7M | 29% | $1,270K |
| $5M+ | 0 | 0% | $0.0M | 0% | — |
| Total | 141 | 100% | $44.4M | 100% | $315K |
🚫 CANCELLATIONS / ON-HOLD / NOT SELECTED
This section covers all studies that were previously Site Selected but subsequently cancelled, placed on hold, or marked as Not Selected — all of which result in removal of awarded FCV from the active portfolio.
TOTAL CANCELLATIONS
33
of 174 gross awards
CANCELLATION RATE (COUNT)
19.0%
Industry benchmark: <10%
CANCELLED FCV
$19.1M
of $63.5M gross FCV
FCV CANCELLATION RATE
30.1%
Gross FCV lost to cancellations
NET FCV (AFTER CANC)
$44.4M
Net realized FCV YEAR
AVG CANCELLED FCV/STUDY
$579K
Avg value lost per cancellation
Monthly Gross vs Cancelled FCV with Cancellation Rate
Gross FCV awarded each year vs cancelled FCV · Cancellation rate % on right axis